Comparison of Biological and Conventional Synthetic DMARDS Treatment Response for Psoriatic Arthritis with Associated Fibromyalgia
DOI:
https://doi.org/10.70749/ijbr.v3i4.1079Keywords:
Psoriatic arthritis, Biologic DMARDs, Conventional synthetic DMARDs, Fibromyalgia, Treatment response, HAQ-DIAbstract
Objective: To compare the good treatment responses of biologic and conventional synthetic DMARDs in psoriatic arthritis (PsA) patients with associated fibromyalgia. Study Design: Randomized controlled trial. Duration and Place of Study: Conducted from January 2024 to December 2024 at the Department of Medicine, CMH Multan. Methodology: A total of 110 patients (age 18-70) with confirmed PsA and fibromyalgia for at least 6 months were randomly assigned into two groups (n=55 each). Group A received biologic DMARDs, including adalimumab, etanercept, infliximab, or secukinumab. Group B received conventional synthetic DMARDs, including methotrexate, leflunomide, or sulfasalazine. The primary endpoint was the therapeutic response at 6 months, measured by Clinical Disease Activity Index (CDAI), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Health Assessment Questionnaire Disability Index (HAQ-DI). Results: Both groups showed significant demographic and clinical variation, but no significant difference was found in the overall therapeutic response between the two groups (p = 0.127). Functional disability, as measured by HAQ-DI, emerged as a key predictor of therapeutic response, with patients exhibiting higher functional impairment showing more favorable treatment outcomes. Conclusion: Biologic and conventional synthetic DMARDs exhibited comparable therapeutic efficacy in PsA patients with fibromyalgia.
Downloads
References
Saalfeld W, Mixon AM, Zelie J, Lydon EJ. Differentiating psoriatic arthritis from osteoarthritis and rheumatoid arthritis: a narrative review and guide for advanced practice providers. Rheumatol Ther.2021;8(4):1493-1517. https://doi.org/10.1007/s40744-021-00365-1
Frede N, Hiestand S, Schauer F, Endres D, Tebartz van Elst L, Zeisbrich M, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther. 2023;10(6):1655-1668. https://doi.org/10.1007/s40744-023-00602-9
Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.
https://doi.org/10.3390/ijms24054901
Hen O, Harrison SR, De Marco G, Marzo-Ortega H. Early psoriatic arthritis: when is the right time to start advanced therapy? Ther Adv Musculoskelet Dis.2024;16. https://doi.org/10.1177/1759720X241266727
D'Onghia M, Ursini F, Cinotti E, Calabrese L, Tognetti L, Cartocci A, et al. Psoriasis and fibromyalgia: a systematic review. J Pers Med. 2024;14(2):165. https://doi.org/10.3390/jpm14020165
Dizner-Golab A, Lisowska B, Kosson D. Fibromyalgia - etiology, diagnosis and treatment including perioperative management in patients with fibromyalgia. Reumatologia. 2023;61(2):137-148 https://doi.org/10.5114/reum/163094
Wilk M, Zimba O, Haugeberg G, Korkosz M. Pain catastrophizing in rheumatic diseases: prevalence, origin, and implications. Rheumatol Int. 2024;44(6):985-1002. https://doi.org/10.1007/s00296-024-05583-8
Elsawy NA, Helal AH, Abd ElHamid HA, Abdel-Fattah YH. Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. Int J Rheum Dis. 2021;24(2):189-196. https://doi.org/10.1111/1756-185X.13987
Lada G, Chinoy H, Talbot PS, Warren RB, Kleyn CE; BADBIR Study Group. Associations between psoriatic arthritis and mental health among patients with psoriasis: a replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health Dis. 2022;2(4):e149. https://doi.org/10.1002/ski2.149
Behrens F, Rech J, Thaçi D, Zinke S, Rothnie KJ, Oefner Daamen C, et al. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: a cross-sectional study. Mod Rheumatol. 2022;32(1):87-95. https://doi.org/10.1080/14397595.2020.1816597
Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844. https://doi.org/10.3389/fimmu.2021.755844
Jacobs ME, Pouw JN, Welsing P, Radstake TRDJ, Leijten EFA. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine. Rheumatology (Oxford). 2021;60(2):780-784.
https://doi.org/10.1093/rheumatology/keaa399
Bergmans BJM, Gebeyehu BY, van Puijenbroek EP, Van Deun K, Kleinberg B, Murk JL, et al. Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis. Rheumatol Ther. 2023;10(5):1147-1165.
https://doi.org/10.1007/s40744-023-00571-z
Persson MSM, Sarmanova A, Doherty M, Zhang W. Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2018;57(10):1830-1837. https://doi.org/10.1093/rheumatology/key131
Momen Majumder MS, Hasan ATMT, Choudhury MR, Ahmed S, Miah MT, Amin MR, et al. 2023 Management recommendations of Bangladesh Rheumatology Society on pharmacological treatment of rheumatoid arthritis with synthetic and biologic disease-modifying drugs. Cureus. 2024;16(4):e59395. https://doi.org/10.7759/cureus.59395
Ettore S, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res. 2019:104473. https://doi.org/10.1016/j.phrs.2019.104473
Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, et al. Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study. Lancet Rheumatol. 2025;7:e44-54.
https://doi.org/10.1016/S2665-9913(24)00221-2
Glintborg B, Di Giuseppe D, Wallman JK, Nordström DC, Gudbjornsson B, Hetland ML, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023;82:820-28. https://doi.org/10.1136/ard-2022-223650
Freites-Nuñez D, Leon L, Toledano E, Candelas G, Martinez C, Rodriguez-Laguna M, et al. Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study. Ther Adv Musculoskelet Dis. 2024;16:1-18.
https://doi.org/10.1177/1759720X241273083
Vallejo-Yagüe E, Burkard T, Möller B, Finckh A, Burden AM. Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in Switzerland. J Clin Med. 2021;10:3194. https://doi.org/10.3390/jcm10143194
Künzler T, Bamert M, Sprott H. Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2024;43:3723-46.
https://doi.org/10.1007/s10067-024-07193-y
Abozaid HS, Khalaf AH, Elgendy DS, Ahmed RHA. Fibromyalgia with psoriatic and rheumatoid arthritis: relationship with disease activity and serum vitamin D level. Egypt Rheumatol Rehabil. 2023;50:32. https://doi.org/10.1186/s43166-023-00202-z
Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17:509-22. https://doi.org/10.1007/s40268-017-0215-7
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
